Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance

Amy S. Clark, Kip A. West, Peter M. Blumberg, Phillip A. Dennis

Research output: Contribution to journalArticle

Abstract

Drugs that target protein kinase C (PKC) are now being evaluated in patients with non-small cell lung cancer (NSCLC), but the role of PKC in NSCLC cells remains unclear. We report here that NSCLC cell lines show enhanced phosphorylation and altered expression of specific PKC isoforms compared with normal lung epithelial cells. PKC inhibition variably increased apoptosis, with rottlerin, a PKCδ inhibitor, being most effective and potentiating chemotherapy-induced apoptosis, especially with trastuzumab. Consistent with PKCδ being anti-apoptotic in NSCLC cells, transient transfection of a kinase-dead mutant of PKCδ increased apoptosis and potentiated chemotherapy-induced apoptosis. Our studies provide a rationale for targeting PKC isoforms in NSCLC cells, especially PKCδ.

Original languageEnglish (US)
Pages (from-to)780-786
Number of pages7
JournalCancer Research
Volume63
Issue number4
StatePublished - Feb 15 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance'. Together they form a unique fingerprint.

  • Cite this